Trusted Resource for Clinical Trials, Protocols & Progress
RMPs serve as a proactive strategy to mitigate known and potential risks. However, no safety profile is static. Emerging data from ongoing studies, post-marketing surveillance, or spontaneous reporting can reveal:
Click to read the full article.
Follow-up information (e.g., hospital discharge summary, lab results) must be submitted as soon as available, usually within 15 days. It should reference the original SAE report ID or EDC entry.
Click to read the full article.
Globally, regulators expect pharmaceutical companies to identify, assess, and mitigate risks associated with new medicinal products. This process is formalized through:
Click to read the full article.
The narrative must summarize the event in a medical and chronological format, typically 1–2 paragraphs, and include:
Click to read the full article.
An RMP is a structured plan that describes the risk-benefit profile of a product and the measures in place to manage its safety. It is required at various stages of product development and approval, including:
Click to read the full article.
Risk minimization activities (RMAs) are proactive and reactive interventions designed to reduce the probability or severity of adverse outcomes during clinical trials. These may include modifying study protocols, educating healthcare professionals, updating labels, or deploying monitoring tools. As per EMA GVP Module V, RMAs must be proportionate to the identified and potential risks and should be reviewed regularly for effectiveness.
Click to read the full article.
During inspections and audits, agencies will review the PI’s role in SAE assessment. Investigators must:
Click to read the full article.
Failing to identify a critical safety risk can jeopardize participant safety, cause trial delays, or even lead to regulatory holds. Conversely, over-focusing on minor risks can lead to inefficiencies. Structured risk identification and prioritization ensures balanced safety oversight and enhances compliance with guidelines such as ICH E2E and GVP Module V.
Click to read the full article.
Regulatory guidance from ICH E2A and E6(R2) defines sponsor roles in pharmacovigilance. Key sponsor responsibilities include:
Click to read the full article.
Unlike late-phase trials, early-phase studies operate under heightened uncertainty. This includes unknown adverse effects, untested pharmacokinetics in humans, and variability in dose-response relationships. An RMP at this stage enables sponsors to:
Click to read the full article.
